Ms. Elizabeth Williams reports

MEDICENNA THERAPEUTICS TO PROVIDE CLINICAL UPDATE FROM PHASE 1/2 ABILITY STUDY ON AUGUST 9, 2023

Medicenna Therapeutics Corp. will host a conference call and live webcast on Aug. 9, 2023, at 8:30 a.m. ET, to provide a clinical update from the phase 1/2 Ability study evaluating MDNA11 in patients with melanoma and other select tumours.

Shareholders and financial analysts are invited to join the live audio webcast either by phone or on-line. Both options to connect to the webcast are described on Medicenna's website.

The webcast will be recorded and will then be available on Medicenna's website following the call.

About Medicenna Therapeutics Corp.

Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 superkines and first-in-class empowered superkines. Medicenna's long-acting IL-2 superkine, MDNA11, is a next-generation IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna's early-stage BiSKITs program (bifunctional superkine immunotherapies) is designed to enhance the ability of superkines to treat immunologically cold tumours. Medicenna's IL-4 empowered superkine, bizaxofusp (formerly MDNA55), has been studied in five clinical trials, including a phase 2b trial for recurrent GBM (glioblastoma multiforme), the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained fast-track status and orphan drug status from the U.S. Food and Drug Administration (FDA) and the FDA/EMA (European Medicines Agency), respectively.